Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Truist Securities reaffirmed its Buy rating and $1,038.00 price target for Eli Lilly and Company (NYSE:LLY) shares, with analyst targets ranging from $580 to $1,190. The company, which has ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Mounjaro and Zepbound have shown impressive prescription growth trends, with Mounjaro experiencing ... saw a 20.7% week-over-week increase to 212,962 scripts in the same period. These products have ...

Mounjaro and Zepbound have shown impressive prescription growth trends ... week increase to 212,962 scripts in the same period. These products have positioned Eli Lilly as a leader in the rapidly ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...

shares of Lilly have dropped by about 13%. The primary reason the stock has been sliding is due to some inconsistent growth trends between Mounjaro and Zepbound over the last quarter. But as I ...